143 related articles for article (PubMed ID: 31238192)
1. Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center.
McIntire P; Khan R; Kilic I; Wojcik EM; Pambuccian SE; Barkan GA
Ann Diagn Pathol; 2019 Aug; 41():124-128. PubMed ID: 31238192
[TBL] [Abstract][Full Text] [Related]
2. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C
Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522
[TBL] [Abstract][Full Text] [Related]
3. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
4. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
5. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Alston ELJ; Zynger DL
Diagn Pathol; 2019 Aug; 14(1):91. PubMed ID: 31419984
[TBL] [Abstract][Full Text] [Related]
6. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
[TBL] [Abstract][Full Text] [Related]
8. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Neal DJ; Amin MB; Smith SC
Diagn Pathol; 2020 May; 15(1):61. PubMed ID: 32456709
[TBL] [Abstract][Full Text] [Related]
9. Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling.
Lawless ME; Tretiakova MS; True LD; Vakar-Lopez F
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):180-185. PubMed ID: 27299187
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
11. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
12. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
Bahceci D; Nguyen JK; Sangoi AR; Stohr BA; Chan E
Hum Pathol; 2023 Jun; 136():56-62. PubMed ID: 36997033
[TBL] [Abstract][Full Text] [Related]
13. Observations on Aron et al's "Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia".
Fellegara G; Gabba S; Dorji T; De Luca G; Colecchia M
Am J Surg Pathol; 2014 Jul; 38(7):1013-5. PubMed ID: 24618606
[No Abstract] [Full Text] [Related]
14. Urothelial carcinoma in situ: diagnostic update.
McKenney JK
Pathology; 2021 Jan; 53(1):86-95. PubMed ID: 33234229
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
Sangoi AR; Falzarano SM; Nicolas M; McKenney JK
Am J Surg Pathol; 2019 Dec; 43(12):1638-1643. PubMed ID: 31368912
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
Yoo D; Min KW; Pyo JS; Kim NY
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763728
[No Abstract] [Full Text] [Related]
18. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
19. Dysplasia and carcinoma in situ of the urinary bladder.
Lopez-Beltran A; Marques RC; Montironi R; Reymundo C; Fonseca J; Cheng L
Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):29-38. PubMed ID: 26072632
[TBL] [Abstract][Full Text] [Related]
20. Iatrogenic pathology of the urinary bladder.
Lopez-Beltran A; Montironi R; Raspollini MR; Cheng L; Netto GJ
Semin Diagn Pathol; 2018 Jul; 35(4):218-227. PubMed ID: 29576423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
